Bridging the Gap in Dialysis Care - Optimizing Hyperphosphatemia Management and Improving Patient Outcomes

Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant, Dietitian, Pharmacist, MBBS
Target Specialties: Nephrology, Nutrition, Pharmacy
Credits Available: 4.5 AMA PRA Category 1 Credit™, Maintenance of Certification (MOC) points available

Chronic kidney disease (CKD) is estimated to impact approximately 37 million individuals in the United States (U.S). Furthermore, about 786,000 persons are living with end-stage kidney disease (ESKD) and receive renal replacement therapy, either through maintenance dialysis or kidney transplantation. Hyperphosphatemia, characterized by phosphorus levels in the bloodstream exceeding the normal parameters of 2.5–4.5 mg/dL, constitutes a critical aspect of the mineral and bone disorder associated with CKD. Elevated levels of serum phosphorus facilitate vascular calcification, impair endothelial function, and may play a role in other newly identified mechanisms of cardiovascular toxicity specific to CKD. The treatment of hyperphosphatemia in patients with CKD requiring dialysis is complex and is ideally managed by a multidisciplinary team of care providers including nephrologists, advanced practice providers (APPs), nurses, dietitians, pharmacists, and other healthcare professionals. Evidence suggests that multidisciplinary care models can slow the progression of CKD and improve mortality rates, but gaps remain in the availability and implementation of these models across different healthcare settings. These challenges include dietary management, optimization of dialysis, pharmacological interventions, patient education, addressing adherence concerns, and the need for comprehensive care models. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with hyperphosphatemia.


CME/CE Accreditation Information

Itinerary

Part 1

Bridging the Gap in Dialysis Care - Optimizing Hyperphosphatemia Management and Improving Patient Outcomes - Baseline Assessment

The following questions are intended to assess your knowledge and practice of key aspects in the management of hyperphosphatemia in CKD patients requiring dialysis..

Module 1:​ Multidisciplinary Unmet Needs in Hyperphosphatemia for Patients on Dialysis

This module will begin with an overview of hyperphosphatemia in CKD, specifically in patients on dialysis, including its prevalence and impact on patient outcomes.

Module 2:​ Mechanism of Action of Therapies for Hyperphosphatemia​

This module will begin with the impact of hyperphosphatemia in chronic kidney disease (CKD). Then we will cover the MoA of phosphate binders broadly. Then we will cover the MoA of tenapanor specifically, contrasting it with phosphate binders.

Module 3:​ Clinical Trials in Hyperphosphatemia Management

This module will begin with evidence for the recently approved tenapanor for hyperphosphatemia. This will encompass three trials leading to its approval. Then, we will cover evidence for more recently approved phosphate binders individually.

Bridging the Gap in Dialysis Care - Optimizing Hyperphosphatemia Management and Improving Patient Outcomes - Final Assessment

The following questions are intended to assess your gained knowledge and practice of key aspects in the management of hyperphosphatemia in CKD patients requiring dialysis..

Live Group Discussion 1

During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with hyperphosphatemia in patients with CKD on dialysis.

Part 2

Patient Case 1 - Josephine's Case

65 yo female on hemodialysis with continued hyperphosphatemia despite treatment with phosphate binders. Considerations for current therapy re-assessment and considerations for add-on therapy.

Patient Case 2 - Noah's Case

72 yo male on hemodialysis with hyperphosphatemia on treatment with phosphate binders with possible sequelae of hyperphosphatemia.

Your Action Plan for Hyperphosphatemia in your patients with CKD Patients Undergoing Dialysis

In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management of hyperphosphatemia in your patients with CKD on dialysis.

Live Group Discussion 2

During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.

Interested in becoming a Group Leader?

Requirements:
Group leaders should be renal experts involved in the management of hyperphosphatemia in CKD patients requiring dialysis. Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

Doug Duffee, MD
Program Director IM Residency
Enroll